+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4896728
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Neoantigen Targeted Therapies Market grew from USD 3.31 billion in 2023 to USD 4.58 billion in 2024. It is expected to continue growing at a CAGR of 38.52%, reaching USD 32.41 billion by 2030.

Neoantigen targeted therapies represent a cutting-edge approach in cancer treatment, focusing on proteins produced by tumor-specific mutations to enhance immunogenicity and offer more personalized medicine. The necessity of these therapies is underscored by their potential to elicit strong immune responses selectively against tumor cells, reducing collateral damage to normal tissues - a pivotal advancement over traditional therapies. Their applications span various oncology fields, augmenting the efficacy of existing immunotherapies such as checkpoint inhibitors and CAR T-cell therapies. End-use primarily involves specialized cancer treatment centers, pharmaceutical companies, and research institutions. Market insights reveal a robust growth trajectory due to ongoing cancer research, advancements in genomic sequencing technologies, and increased government funding. However, the complexity of identifying and validating neoantigens, high development costs, and regulatory challenges pose significant barriers. The Personalized Immunotherapy sector is expected to drive demand due to the increasing focus on precision medicine and patient-specific treatment protocols. Opportunities lie in leveraging AI and bioinformatics to streamline neoantigen identification and in developing combinational therapies that enhance treatment efficacy. Increasing collaborations between biotech firms and academic institutions are opening new pathways for innovation. Key recommendations include investing in technology to improve identification and validation processes for neoantigens and exploring partnerships to enhance research capabilities. Moreover, advancing clinical trial designs with adaptive and seamless phases can address cost and regulatory challenges by enhancing efficiency and efficacy data exposure. Limitations such as high costs, technical complexities in neoantigen identification, and stringent regulatory protocols remain challenging factors. Future areas of innovation include enhancing the accuracy of neoantigen prediction models, exploring novel delivery mechanisms, and improving patient stratification techniques to enhance therapy personalization. The market is dynamic, with rapid technological advancements and a competitive landscape influenced by biotech companies and healthcare providers focused on improving cancer treatment outcomes.

Understanding Market Dynamics in the Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rise in the popularity of neoantigen targeted therapies
    • Surge in number of cancer patients
    • Increase in the geriatric population across the globe
    • Developing healthcare infrastructure
  • Market Restraints
    • Side effects associated with neoantigen targeted therapies
  • Market Opportunities
    • Technological advancement in the cancer treatment
    • Increasing government investment such as reimbursement plan
  • Market Challenges
    • Challenges of neoantigen identification

Exploring Porter’s Five Forces for the Neoantigen Targeted Therapies Market

Porter’s Five Forces framework further strengthens the insights of the Neoantigen Targeted Therapies Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Neoantigen Targeted Therapies Market

External macro-environmental factors deeply influence the performance of the Neoantigen Targeted Therapies Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Targeted Therapies Market, highlighting leading vendors and their innovative profiles. These include Achilles Therapeutics PLC, Advaxis, Inc., Bavarian Nordic, BioNTech SE, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genocea Biosciences, Inc., Gradalis, Inc., Gritstone bio, Inc., IOVANCE Biotherapeutics, Inc., ISA Pharmaceuticals B.V., Medigene AG, Merck & Co., Inc., and Precision Biologics.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Targeted Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Target Disease Indication
    • Bone Cancer
    • Colorectal Cancer
    • Gynecological Cancer
    • Non-Small Cell Lung Cancer
    • Renal Cell Carcinoma
  • Neoantigens Type
    • Off-the-Shelf Neoantigens
    • Personalized Neoantigens
  • Immunotherapy Type
    • Dendritic Cell Vaccines
    • DNA / RNA-Based Vaccines
    • Protein / Peptide-based Vaccines
    • TIL-Based Therapies
  • Route of Administration
    • Intradermal
    • Intravenous
    • Subcutaneous
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the popularity of neoantigen targeted therapies
5.1.1.2. Surge in number of cancer patients
5.1.1.3. Increase in the geriatric population across the globe
5.1.1.4. Developing healthcare infrastructure
5.1.2. Restraints
5.1.2.1. Side effects associated with neoantigen targeted therapies
5.1.3. Opportunities
5.1.3.1. Technological advancement in the cancer treatment
5.1.3.2. Increasing government investment such as reimbursement plan
5.1.4. Challenges
5.1.4.1. Challenges of neoantigen identification
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Neoantigen Targeted Therapies Market, by Target Disease Indication
6.1. Introduction
6.2. Bone Cancer
6.3. Colorectal Cancer
6.4. Gynecological Cancer
6.5. Non-Small Cell Lung Cancer
6.6. Renal Cell Carcinoma
7. Neoantigen Targeted Therapies Market, by Neoantigens Type
7.1. Introduction
7.2. Off-the-Shelf Neoantigens
7.3. Personalized Neoantigens
8. Neoantigen Targeted Therapies Market, by Immunotherapy Type
8.1. Introduction
8.2. Dendritic Cell Vaccines
8.3. DNA / RNA-Based Vaccines
8.4. Protein / Peptide-based Vaccines
8.5. TIL-Based Therapies
9. Neoantigen Targeted Therapies Market, by Route of Administration
9.1. Introduction
9.2. Intradermal
9.3. Intravenous
9.4. Subcutaneous
10. Americas Neoantigen Targeted Therapies Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Neoantigen Targeted Therapies Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Neoantigen Targeted Therapies Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. NEOANTIGEN TARGETED THERAPIES MARKET RESEARCH PROCESS
FIGURE 2. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NEOANTIGEN TARGETED THERAPIES MARKET DYNAMICS
TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 39. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 40. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 41. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 43. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 44. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 45. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 62. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 63. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 65. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 73. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 74. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 97. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 98. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 99. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 110. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 111. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 112. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 114. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 115. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 116. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 118. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 119. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 120. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 135. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 136. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 146. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 147. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 150. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 151. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 152. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 154. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 155. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 156. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 172. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 182. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 183. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 184. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Neoantigen Targeted Therapies Market, which are profiled in this report, include:
  • Achilles Therapeutics PLC
  • Advaxis, Inc.
  • Bavarian Nordic
  • BioNTech SE
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genocea Biosciences, Inc.
  • Gradalis, Inc.
  • Gritstone bio, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • ISA Pharmaceuticals B.V.
  • Medigene AG
  • Merck & Co., Inc.
  • Precision Biologics

Methodology

Loading
LOADING...

Table Information